Top Story

New and upcoming therapies for the treatment of HCV

October 21, 2014

PHILADELPHIA — In this exclusive video interview, Paul Y. Kwo, MD, professor of medicine , Indiana University, discusses the new and upcoming therapies, including the recently approved combination regimen of ledipasvir and sofosbuvir, to treat patients with hepatitis C virus infection. He further discusses how the new therapies will impact patients within this specific population in the future.

“With a lot of hard work, we should be able to successfully treat and eradicate this disease within the next several decades,” Kwo said.

Meeting News Coverage

Main source of S. aureus differed for community- and hospital-acquired infections

October 21, 2014
PHILADELPHIA — Data presented at IDWeek 2014 suggest soft tissue infections are the main source in community-acquired Staphylococcus aureus blood stream…
figure Meeting News Coverage

Ceftolozane/tazobactam shows promise against gram-negative infections

October 21, 2014
PHILADELPHIA — Phase 3 study data indicate the novel combination antibiotic ceftolozane/tazobactam achieved high clinical and microbiological cure rates in…
figure Meeting News CoverageVideo

Integrase inhibitors favorable as initial HIV therapy

October 20, 2014
PHILADELPHIA — Joel Gallant, MD, MPH, of the Southwest Care Center in Santa Fe, N.M., and outgoing chair of the HIVMA, gives an overview of his talk at IDWeek…
More News Headlines »
CME
figure

HCV Consults: Volume 1, Number 1

This activity is supported by educational grants from AbbVie and Genentech.

Physicians seldom experience a paradigm shift in disease management as great as that transpiring in HCV therapy. With…
More »
Meeting News Coverage Video
figure

Integrase inhibitors favorable as initial HIV therapy

October 20, 2014
PHILADELPHIA — Joel Gallant, MD, MPH, of the Southwest Care Center in Santa Fe, N.M., and outgoing chair of the…
More »
CME
figure

Challenges in HIV Screening and Prophylaxis: PrEP’ing for the Future

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

A substantial proportion of Americans with HIV remain undiagnosed and suboptimally treated. Failure to follow…
More »